Kurve Therapeutics

Growth Stage

Bypassing the Blood-Brain Barrier

Analytics

Platform

Rialto Markets

Start Date

08/03/2022

Close Date

08/03/2023

Min. Goal

$580

Max. Goal

$50,000,000

Min. Investment

$580

Security Type

Equity - Common

Funding Type

RegA+

Series

Series A

Price Per Share

$5.80

Pre-Money Valuation

$291,787,299

Location

Lynnwood, Washington

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B

Margin

Medium

Capital Intensity

High

Business Type

Growth

Kurve Therapeutics is raising funds through Reg A+ crowdfunding with Rialto Markets as the Broker-Dealer. The company has developed its patented Controlled Particle Dispersion (CPD) intranasal drug delivery technology. The technology creates a focused flow through the curved pathways of the nasal cavity and allows access to the olfactory region to treat neurogenerative diseases. Kurve Therapeutics’ technology has been featured in multiple publications and has completed Phase II studies on Alzheimer’s patients. Marc Giroux, Tom McDowell, and Glenn Cornett founded Kurve Therapeutics in 2019. The current crowdfunding campaign has a maximum target of $50,000,000. The campaign proceeds will be used for asset purchase, marketing, clinical studies, contract manufacturing, and working capital.

Balance Sheet

Cash and Cash Equivalents

$373,804

Accounts and Notes Receivable

$15,000

Total Assets

$640,574

Accounts Payable & Accrued Liabilities

$28,331

Long Term Debt

$507,500

Total Liabilities

$606,726

Total Stockholders' Equity

$33,848

Total Liabilities and Equity

$640,574

Statement of Comprehensive Income Information

Total Revenues

$70,700

Costs & Expenses Applicable to Rev

$128,344

Net Income

$-65,427

Earnings Per Share - Basic

$0.00

Earnings Per Share - Diluted

$0.00

Auditor: Assurance Dimensions
Financials as of: 08/03/2022
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings (excluding risk)
Advanced company search ( with ratings)
Markets page filters and historical industry data
Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd's qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
Search and filter based on Analyst Reports
In-depth risk ratings for every raise
Get Edge Pro Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Analyst Report Analyst Report Methodology Article

No company has been able to develop an FDA-approved treatment that stops Alzheimer’s in its tracks. Kurve Therapeutics has the potential to change that with its potentially groundbreaking device. But its long road to FDA approval and its inexperienced team may threaten the company’s survival.

Upgrade to view full report

Create your first portfolio

Create your very own investment portfolio on KingsCrowd.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Kurve Therapeutics on Rialto Markets 2022
$
Platform: Rialto Markets
Security Type: Equity - Common
Valuation: $291,787,299

Follow company

Follow Kurve Therapeutics on Rialto Markets 2022
View on Rialto Markets
Bullish / Bearish
You're Bullish on Kurve Therapeutics on Rialto Markets 2022

Thank you for your vote on Kurve Therapeutics on Rialto Markets 2022

Bullish / Bearish
You're Bearish on Kurve Therapeutics on Rialto Markets 2022

Thank you for your vote on Kurve Therapeutics on Rialto Markets 2022